UBS Group’s bluebird bio BLUE Stock Holding History

UBS Group’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-733	Closed	-$411K	–	9007
2020 Q4	$411K	Hold	733	–	–	﹤0.01%	4760
2020 Q3	$513K	Hold	733	–	–	﹤0.01%	4175
2020 Q2	$580K	Hold	733	–	–	﹤0.01%	4013
2020 Q1	$437K	Hold	733	–	–	﹤0.01%	4089
2019 Q4	$834K	Buy	+733	New	+$797K	﹤0.01%	4374
2015 Q1	–	Sell	-39	Closed	-$46K	–	8822
2014 Q4	$46K	Buy	+39	New	+$26.1K	﹤0.01%	6583

Other funds holding BLUE

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's BLUE Position: Q2 2025 in Review

UBS Group sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 51,804 shares — an estimated $253K sold.

UBS Group first reported a position in BLUE in Q4 2014 and held it in 42 quarters. The position peaked at $9.37M in Q4 2015. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

UBS Group reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
UBS Group sold 51,804 bluebird bio shares in Q2 2025, an estimated $253K.
UBS Group first reported a position in bluebird bio in Q4 2014 and held it in 42 quarters.
UBS Group's bluebird bio position peaked at $9.37M in Q4 2015.
3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.